BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomed Res Int 2017;2017:9856140. [PMID: 29349087 DOI: 10.1155/2017/9856140] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Alexandraki KI, Angelousi A, Chatzellis E, Chrisoulidou A, Kalogeris N, Kanakis G, Savvidis C, Vassiliadi D, Spyroglou A, Kostopoulos G, Markussis V, Toulis K, Tsagarakis S, Kaltsas GA. The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis. J Pers Med 2023;13. [PMID: 36836538 DOI: 10.3390/jpm13020304] [Reference Citation Analysis]
2 Sperling F, Misiak D, Hüttelmaier S, Michl P, Griesmann H. IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2. Cancers 2022;14:2121. [DOI: 10.3390/cancers14092121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Anaridha S, Imran PM, Meeran IS, Shabeer T. Comparative theoretical analysis using DFT & MP2 calculations, ADMET profiling and docking studies of the drug telotristat ethyl. Journal of the Indian Chemical Society 2021;98:100248. [DOI: 10.1016/j.jics.2021.100248] [Reference Citation Analysis]
4 Spyroglou A, Bramis K, Alexandraki KI. Neuroendocrine neoplasms: Evolving and future treatments. Current Opinion in Endocrine and Metabolic Research 2021;19:15-21. [DOI: 10.1016/j.coemr.2021.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Aburjania Z, Whitt JD, Jang S, Nadkarni DH, Chen H, Rose JB, Velu SE, Jaskula-Sztul R. Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells. Molecules 2020;25:E4940. [PMID: 33114525 DOI: 10.3390/molecules25214940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Flórez NF, Pérez Cadavid JC, Turizo Agámez Á, Cuesta Castro DP. Caracterización de pacientes con tumores neuroendocrinos en un hospital de referencia de alta complejidad. Rev Colomb Cir 2020;35:639-46. [DOI: 10.30944/20117582.786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Liu H, Xie R, Zhao Z, Xu D, Yang K, Ding M, Tan D, Liao W, Han X, Zhang J, Shen D, Yuan J, Xu Z, Fei J. An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm. Medicine (Baltimore) 2020;99:e21682. [PMID: 32872039 DOI: 10.1097/MD.0000000000021682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Malczewska A, Procner A, Walter A, Kusnierz K, Zajecki W, Aslanian H, Kos-Kudla B. The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK. BMC Gastroenterol 2020;20:235. [PMID: 32703157 DOI: 10.1186/s12876-020-01348-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
9 Desai GS, Pande P, Chhabra V, Shah RC, Jagannath P. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years. Indian J Gastroenterol 2019;38:399-410. [PMID: 31802438 DOI: 10.1007/s12664-019-00957-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol 2019;10:674-87. [PMID: 31392048 DOI: 10.21037/jgo.2019.03.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Barthet M. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumor. Ann Endocrinol (Paris) 2019;80:182-4. [PMID: 31053252 DOI: 10.1016/j.ando.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Alexandraki KI, Tsoli M, Kyriakopoulos G, Angelousi A, Nikolopoulos G, Kolomodi D, Kaltsas GA. Current concepts in the diagnosis and management of neuroendocrine neoplasms of unknown primary origin. Minerva Endocrinol 2019;44:378-86. [PMID: 30991795 DOI: 10.23736/S0391-1977.19.03012-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lyseng-Williamson KA. Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea. Drugs. 2018;78:941-950. [PMID: 29931594 DOI: 10.1007/s40265-018-0935-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
14 Moore AR, Yip VS. Treatment of Neuroendocrine Tumour Disease. Liver Cancers 2019. [DOI: 10.1007/978-3-319-92216-4_20] [Reference Citation Analysis]
15 Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, Lepareur N. Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres. Biomed Res Int 2018;2018:1435302. [PMID: 30687734 DOI: 10.1155/2018/1435302] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
16 Graham C, Chauhan A, Anthony L. Can a High-grade Neuroendocrine Carcinoma be Functional? Am J Med Sci 2019;357:258-62. [PMID: 30638597 DOI: 10.1016/j.amjms.2018.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Klieser E, Urbas R, Swierczynski S, Stättner S, Primavesi F, Jäger T, Mayr C, Kiesslich T, Fazio PD, Helm K, Neureiter D. HDAC-Linked "Proliferative" miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors. Int J Mol Sci 2018;19. [PMID: 30223590 DOI: 10.3390/ijms19092781] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
18 Døssing KBV, Kjær C, Vikeså J, Binderup T, Knigge U, Culler MD, Kjær A, Federspiel B, Friis-Hansen L. Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells. Genes (Basel) 2018;9:E337. [PMID: 29973528 DOI: 10.3390/genes9070337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kyriakopoulos G, Mavroeidi V, Chatzellis E, Kaltsas GA, Alexandraki KI. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med. 2018;6:252. [PMID: 30069454 DOI: 10.21037/atm.2018.06.27] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
20 Inbal Uri, Alexandraki K, Grozinsky-glasberg S. Gastrointestinal Hormones in Cancer. Encyclopedia of Endocrine Diseases 2018. [DOI: 10.1016/b978-0-12-801238-3.95875-6] [Reference Citation Analysis]
21 Alexandraki K, Angelousi A, Boutzios G, Kyriakopoulos G, Rontogianni D, Kaltsas G. Management of neuroendocrine tumors of unknown primary. Rev Endocr Metab Disord 2017;18:423-31. [PMID: 29199361 DOI: 10.1007/s11154-017-9437-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]